Matches in Wikidata for { <http://www.wikidata.org/entity/Q65473779> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q65473779 description "clinical trial" @default.
- Q65473779 description "ensayu clínicu" @default.
- Q65473779 description "klinisch onderzoek" @default.
- Q65473779 description "клінічне випробування" @default.
- Q65473779 name "Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes" @default.
- Q65473779 name "Efficacy and Safety of BI 1356 BS" @default.
- Q65473779 type Item @default.
- Q65473779 label "Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes" @default.
- Q65473779 label "Efficacy and Safety of BI 1356 BS" @default.
- Q65473779 prefLabel "Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes" @default.
- Q65473779 prefLabel "Efficacy and Safety of BI 1356 BS" @default.
- Q65473779 P1050 Q65473779-B2B50310-59BD-488C-8C19-0AC835E9C86B @default.
- Q65473779 P1132 Q65473779-5BDB75BE-A70A-482A-BFA8-08AB8E0C63BA @default.
- Q65473779 P1476 Q65473779-4847A3F5-010E-4509-8C79-AB73F7DD52D0 @default.
- Q65473779 P17 Q65473779-3F87028F-4222-4669-877A-8F7EBCFB9EA3 @default.
- Q65473779 P17 Q65473779-5FBECB11-F834-44B8-A76A-4FC77AEE798E @default.
- Q65473779 P17 Q65473779-ABE8773C-C732-42C5-B17C-0C6FF30DEAD3 @default.
- Q65473779 P17 Q65473779-C30EFEB9-BC65-4F11-A2B2-22115BF73E33 @default.
- Q65473779 P17 Q65473779-DE50F0D6-A77B-475F-94F9-DAF324915DE4 @default.
- Q65473779 P17 Q65473779-E6223B04-6D4C-4137-9921-84310A1400BB @default.
- Q65473779 P2899 Q65473779-1245FA93-3686-44FA-9A35-4860AA3DF276 @default.
- Q65473779 P3098 Q65473779-16C852E9-F8ED-4D25-A456-3E47B25A30EB @default.
- Q65473779 P31 Q65473779-5D20E3BA-85F4-45D7-8D06-0A1D95119393 @default.
- Q65473779 P4135 Q65473779-ECAFA401-F191-4B46-9FBB-63201207E7D0 @default.
- Q65473779 P4844 Q65473779-17AC2B65-0826-4C13-A5F7-AD6D2268C36B @default.
- Q65473779 P4844 Q65473779-4FC4FED7-51C6-417A-A3E5-1E82D1E1AD40 @default.
- Q65473779 P4844 Q65473779-975241AD-C46D-45BE-927D-CEB178F7F68E @default.
- Q65473779 P580 Q65473779-C975F803-B8F6-40AB-B85E-8AA9E9A0A2EA @default.
- Q65473779 P582 Q65473779-9CF60B57-690E-4D29-95BA-F96B2EF69D9C @default.
- Q65473779 P6099 Q65473779-C8ABB7E1-0BD3-4CD8-8612-4361DBB4ED57 @default.
- Q65473779 P8363 Q65473779-ECA2C8C1-14EE-4ECA-9673-797227F9322E @default.
- Q65473779 P1050 Q12206 @default.
- Q65473779 P1132 "+333" @default.
- Q65473779 P1476 "A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as add-on Therapy in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Metformin Therapy, Including an Open-label Glimepiride Treatment Arm." @default.
- Q65473779 P17 Q142 @default.
- Q65473779 P17 Q145 @default.
- Q65473779 P17 Q183 @default.
- Q65473779 P17 Q212 @default.
- Q65473779 P17 Q214 @default.
- Q65473779 P17 Q34 @default.
- Q65473779 P2899 "+21" @default.
- Q65473779 P3098 "NCT00309608" @default.
- Q65473779 P31 Q30612 @default.
- Q65473779 P4135 "+75" @default.
- Q65473779 P4844 Q19484 @default.
- Q65473779 P4844 Q425027 @default.
- Q65473779 P4844 Q909745 @default.
- Q65473779 P580 "2006-04-01T00:00:00Z" @default.
- Q65473779 P582 "2007-08-01T00:00:00Z" @default.
- Q65473779 P6099 Q42824440 @default.
- Q65473779 P8363 Q78089383 @default.